Aprea Therapeutics
APRE
Aprea Therapeutics (APRE) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.53
- EPS estimate
- −$0.71
- EPS surprise
- +25.49%
- Revenue surprise
- +0.00%
- Revenue
- $118,111.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.71 | −$0.53 | +25.49% | $118,111.00 | SEC |
| Q1 2025 | May 14, 2025 | −$0.65 | −$0.66 | −0.87% | $162,463.00 | SEC |
| Q4 2024 | Mar 25, 2025 | −$0.66 | −$0.49 | +25.76% | $205,817.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.72 | −$0.64 | +10.66% | $354,621.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.62 | −$0.58 | +5.89% | $561,574.00 | SEC |
| Q1 2024 | May 14, 2024 | −$0.76 | −$0.67 | +11.84% | $380,569.00 | SEC |
| Q4 2023 | Mar 26, 2024 | −$0.77 | −$0.92 | −19.99% | $14,075.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$1.13 | −$0.86 | +23.67% | $319,468.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$1.43 | −$0.87 | +38.95% | $249,688.00 | SEC |
| Q1 2023 | May 15, 2023 | −$1.51 | −$1.34 | +10.96% | $0.00 | SEC |
| Q4 2022 | Mar 30, 2023 | −$2.60 | −$0.92 | +64.62% | $0.00 | SEC |
| Q3 2022 | Nov 9, 2022 | −$5.40 | −$2.40 | +55.56% | $0.00 | — |
| Q2 2022 | Aug 11, 2022 | −$6.20 | −$86.80 | −1300.00% | $0.00 | — |
| Q1 2022 | May 16, 2022 | −$7.60 | −$7.20 | +5.26% | $0.00 | — |
| Q4 2021 | Mar 15, 2022 | −$8.80 | −$7.20 | +18.18% | $0.00 | — |
| Q3 2021 | Nov 8, 2021 | −$9.05 | −$9.00 | +0.55% | $0.00 | — |
| Q2 2021 | Aug 12, 2021 | −$9.35 | −$9.60 | −2.67% | $0.00 | — |
| Q1 2021 | May 6, 2021 | −$9.85 | −$9.20 | +6.60% | $0.00 | — |
| Q4 2020 | Mar 16, 2021 | −$13.64 | −$14.60 | −7.04% | $0.00 | — |
| Q3 2020 | Nov 5, 2020 | −$15.20 | −$11.60 | +23.68% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Aprea Therapeutics (APRE) last report earnings?
Aprea Therapeutics last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did APRE beat earnings estimates?
Yes. Aprea Therapeutics reported EPS of −$0.53 for Q2 2025 against a −$0.71 estimate — a 25.49% beat.
How much revenue did APRE report last quarter?
Aprea Therapeutics reported $118,111.00 in revenue for Q2 2025.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.